2018 Kudo M Gastrointest Endosc, Kudo M Lancet Gastroenterol Hepatol Kudo M Biochem Biophys Res Commun Kudo M J Med Ultrason Kudo M Dig Endosc

Transcription

1 2018 英文論文 Kamata K, Takenaka M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, Kudo M: Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. Gastrointest Endosc, 87: , 2018 (IF=7.204) Kudo M, Cheng AL, Park JW, Park JH, Liang PC, Hidaka H, Izumi N, Heo J, Lee YJ, Sheen IS, Chiu CF, Arioka H, Morita S, Arai Y: Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol 3:37-46, 2018 (IF=0.000) Nishiyama H, Nagai T, Kudo M, Okazaki Y, Azuma Y, Watanabe T, Goto S, Ogata H, Sakurai T: Supplementation of pancreatic digestive enzymes alters the composition of intestinal microbiota in mice. Biochem Biophys Res Commun 459: , 2018 (IF=2.466) Minaga K, Takenaka M, Omoto S, Miyata T, Kamata K, Yamao K, Imai H, Watanabe T, Kitano M, Kudo M: A case of successful transluminal drainage of walled-off necrosis under contrast-enhanced harmonic endoscopic ultrasonography guidance. J Med Ultrason 45: , 2018 (IF=0.455) Kamata K, Takenaka M, Kitano M, Omoto S, Miyata T, Minaga K, Yamao K, Imai H, Sakurai T, Nishida N, Kashida H, Chikugo T, Chiba Y, Nakai T, Takeyama Y, Lisotti A, Fusaroli P, Kudo M: Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of localized gallbladder lesions. Dig Endosc 30:98-106, 2018 (IF=3.238) Takayasu K, Arii S, Sakamoto M, Matsuyama Y, Kudo M, Kaneko S, Nakashima O, Kadoya M, Izumi N, Takayama T, Ku Y, Kumada T, Kubo S, Kokudo T, Hagiwara Y, Kokudo N; Liver Cancer Study Group of Japan: Impact of resection and ablation for single hypovascular hepatocellular

2 carcinoma 2 cm analysed with propensity score weighting. Liver Int 38: , 2018 (IF=4.500) Kudo M: Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma. Liver Cancer 7:1-19, 2018 (IF=7.854) Kudo M: Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer 7:20-27, 2018 (IF=7.854) Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391: , 2018 (IF=53.254) Matsui S, Kashida H, Kudo M: Gastric inverted hyperplastic polyp mimicking a papilla. Am J Gastroenterol 113:462, 2018 (IF=10.231) Minami Y, Kudo M: Hepatitis C virus-induced cryoglobulinemic vasculitis. Brain Nerve 70: , 2018 (IF=0.000) Ikeda M, Kudo M, Aikata H, Nagamatsu H, Ishii H, Yokosuka O, Torimura T, Morimoto M, Ikeda K, Kumada H, Sato T, Kawai I, Yamashita T, Horio H, Okusaka T, Miriplatin TACE Study Group: Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastoroenterol 53: , 2018 (IF=5.561) Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M: Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of

3 hepatocellular carcinoma. Eur Radio 28: , 2018 (IF=4.027) Minaga K, Takenaka M, Kamata K, Kudo M: Transrectal endoscopic ultrasound-guided paracentesis for diagnosis of malignant ascites in the pelvis. Dig Liver Dis 50:311, 2018 (IF=3.287) Kono M, Komeda Y, Sakurai T, Okamoto A, Minaga K, Kamata K, Hagiwara S, Inoue H, Enoki E, Matsumura I, Watanabe T, Kudo M: Induction of complete remission by azacitidine in a patient with myelodysplastic syndrome-associated inflammatory bowel disease. J Crohns Colitis 12: , 2018 (IF=6.637) Kudo M, Kang YK, Park JW, Qin S, Inaba Y, Assenat E, Umeyama Y, Lechuga MJ, Valota O, Fujii Y, Martini JF, Williams JA, Obi S: Regional differences in efficacy, safety and biomarkers for second-line axitinib in patients with advanced hepatocellular carcinoma: from a randomized phase II study. Liver Cancer, 7: , 2018 (IF=7.854) Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group: Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3: , 2018 (IF=0.000) Minaga K, Watanabe T, Kamata K, Asano N, Kudo M: Nucleotide-binding oligomerization domain 1 and Helicobacter pylori infection: A review. World J Gastroenterol 24: , 2018 (IF=3.300) Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR: Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev 68:16-24, 2018 (IF=8.122).

4 Kudo M: Cabozantinib as a second-line agent in advanced hepatocellular carcinoma. Liver Cancer 7: , 2018 (IF=7.854) Kudo M: Management of hepatocellular carcinoma in Japan as a world-leading model. Liver Cancer 7: , 2018 (IF=7.854) Matsui S, Kashida H, Kudo M: Utility of endoscopic ultrasound in hemorrhage from recurrent duodenal varices. Ann Gastroenterol 31:636, 2018 (IF=0.000) Minaga K, Takenaka M, Okamoto A, Omoto S, Miyata T, Imai H, Kudo M: Reintervention for stent occlusion after endoscopic ultrasound-guided hepaticogastrostomy with novel use of a precut needle-knife. Endoscopy 50: E , 2018 (IF=6.629) Minaga K, Takenaka M, Kamata K, Yoshikawa T, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakamoto H, Kitano M, Kudo M: Alleviating pancreatic cancer-associated pain using endoscopic ultrasound-guided neurolysis. Cancers (Basel) 10:E50, 2018 (IF=5.326) Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX: Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Brit J Cancer 119:19-26, 2018 (IF=5.922) Yen CJ, Muro K, Kim TW, Kudo M, Shih JY, Lee KW, Chao Y, Kim SW, Yamazaki K, Sohn J, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Chung HC: Ramucirumab safety in East Asian patients: A meta-analysis

5 of six global, randomized, double-blind, placebo-controlled, phase III clinical trials. J Glob Oncol:1-12, 2018 (IF=0.000) Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus, SW, Ma J, Siegel AB, Cheng AL, Kudo M, for the KEYNOTE-224 investigators: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19: , 2018 (IF=36.418) Okamoto K, Watanabe T, Komeda Y, Okamoto A, Minaga K, Kamata K, Yamao K, Takenaka M, Hagiwara S, Sakurai T, Tanaka T, Sakamoto H, Fujimoto K, Nishida N, Kudo M: Dysbiosis-associated polyposis of the colon-cap polyposis. Front Immunol 9:918, 2018 (IF=5.511) Nishida N, Kudo M: Immune checkpoint blockade for the treatment of human hepatocellular. Hepatol Res 48: , 2018 (IF=3.415) Dietrich CF, Averkiou M, Nielsen MB, Barr RG, Burns PN, Calliada F, Cantisani V, Choi B, Chammas MC, Clevert DA, Claudon M, Correas JM, Cui XW, Cosgrove D, D'Onofrio M, Dong Y, Eisenbrey J, Fontanilla T, Gilja OH, Ignee A, Jenssen C, Kono Y, Kudo M, Lassau N, Lyshchik A, Franca Meloni M, Moriyasu F, Nolsøe C, Piscaglia F, Radzina M, Saftoiu A, Sidhu PS, Sporea I, Schreiber-Dietrich D, Sirlin CB, Stanczak M, Weskott HP, Wilson SR, Willmann JK, Kim TK, Jang HJ, Vezeridis A, Westerway S: How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open 4:E2-15, 2018 (IF=0.000) Yamao K, Kitano M, Takenaka M, Minaga K, Sakurai T, Watanabe T, Kayahara T, Yoshikawa T, Yamashita Y, Asada M, Okabe Y, Hanada K, Chiba Y, Kudo M: Outcomes of endoscopic biliary drainage in pancreatic

6 cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in west Japan. Gastrointest Endosc 88:66-75, 2018 (IF=7.204) Takenaka M, Arisaka Y, Sakai A, Kobayashi T, Shiomi H, Masuda A, Kudo M: A novel biliary cannulation method for difficult cannulation cases using a unique, uneven, double-lumen cannula (Uneven method). Endoscopy 50:E , 2018 (IF=6.629) Takenaka M, Yamao K, Kudo M: Novel method of biliary cannulation for patients with Roux-en-Y anastomosis using a unique, uneven, double lumen cannula (Uneven method). Dig Endosc 30: , 2018 (IF=3.238) Yoshida A, Hagiwara S, Watanabe T, Nishida N, Ida H, Sakurai T, Komeda Y, Yamao K, Takenaka M, Enoki E, Kimura M, Miyake M, Kawada A, Kudo M: Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy. Intern Med 57: , 2018 (IF=0.817) Watanabe T, Minaga K, Kamata K, Kudo M, Strober W: Mechanistic insights into autoimmune pancreatitis and IgG4-related disease. Trends Immunol 39: , 2018 (IF=14.188) Kudo M: Proposal of primary endpoints for TACE combination trials with systemic therapy: Lessons learned from 5 negative trials and the positive TACTICS trial. Liver Cancer 7: , 2018 (IF=7.854) Kudo M: Extremely high objective response rate of Lenvatinib: Its clinical relevance and changing the treatment paradigm in hepatocellular

7 carcinoma. Liver Cancer 7: , 2018 (IF=7.854) Takenaka M, Minaga K, Kudo M: Cannulation method for intra-diverticular papilla with long oral protrusion using biopsy forceps for axis alignment. Dig Endosc 30: , 2018 (IF=3.238) Kamata K, Takenaka M, Minaga K, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Kudo M: Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. Endosc Ultrasound 7: , 2018 (IF=3.323) Tanaka H, Kamata K, Takenaka M, Kudo M: Contrast-enhanced harmonic EUS image of pancreatic mucinous cystadenocarcinoma. Internal Med 57: , 2018 (IF=0.817) Tamaki N, Koizumi Y, Hirooka M, Yada N, Takada H, Nakashima O, Kudo M, Hiasa Y, Izumi N: Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. Hepatol Res 48: , 2018 (IF=3.415) Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Nakai A, Tanaka H, Chiba Y, Watanabe T, Sakurai T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, Kitano M, Kudo M: Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. Digest Endosc 30: , 2018 (IF=3.238) Tak WY, Ryoo BY, Lim HY, Kim DY, Okusaka T, Ikeda M, Hidaka H, Yeon JE, Mizukoshi E, Morimoto M, Lee MA, Yasui K, Kawaguchi Y, Heo J, Morita S, Kim TY, Furuse J, Katayama K, Aramaki T, Hara R, Kimura T, Nakamura O, Kudo M: Phase I/II study of first-line combination therapy

8 with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients. Invest New Drugs, 2018 (epub ahead of print) (IF=3.484) Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, Weissinger F, Brandi G, Barone CA, Okusaka T, Wada Y, Park JO, Ryoo BY, Cho JY, Chung HC, Li CP, Yen CJ, Lee KD, Yang L, Abada PB, Chang SC, Chau I: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Analysis of REACH Trial results by Child-Pugh score. JAMA Oncol, 2018 (epub ahead of print) (IF=20.871) Kaibori M, Yoshii K, Yokota I, Hasegwa K, Nagashima F, Kubo S, Kon M, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N: Liver Cancer Study Group of Japan: Impact of advanced age on survival in patients undergoing resection of hepatocellular carcinoma: report of a Japanese nationwide survey. Ann Surg 2018 (epub ahead of print) (IF=9.203) Minaga K, Kitano M, Itonaga M, Imai H, Miyata T, Yamao K, Tamura T, Nuta J, Warigaya K, Kudo M: Endoscopic ultrasound-guided biliary drainage using a newly designed metal stent with a thin delivery system: A preclinical study in phantom and porcine models. J Med Ultrason, 2018 (epub ahead of print) (IF=0.455) Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M: Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B. Antivir Ther 2018 (epub ahead of print) (IF=2.594) Kamata K, Watanabe T, Minaga K, Strober W, Kudo M: Autoimmune pancreatitis mouse model. Curr Protoc Immunol 2018 (epub ahead of

9 print) (IF=0.000) Kaibori M, Yoshii K, Hasegawa K, Ogawa A, Kubo S, Tateishi R, Izumi N, Kadoya M, Kudo M, Kumada T, Sakamoto M, Nakashima O, Matsuyama Y, Takayama T, Kokudo N; Liver Cancer Study Group of Japan: Treatment optimization for hepatocellular carcinoma in elderly patients in a Japanese nationwide cohort. Ann Surg 2018(epub ahead of print) (IF=9.203) Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hirasa Y, Michitaka K, Kudo M, on behalf of the RELPEC Study Group of HCC 48 Group: Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis. Liver Cancer, 2018 (epub ahead of print) (IF=7.854) Sofue K, Tsurusaki M, Mileto A, Hyodo T, Sasaki K, Nishii T, Chikugo T, Yada N, Kudo M, Sugimura K, Murakami T: Dual-energy computed tomography for non-invasive staging of liver fibrosis: Accuracy of iodine density measurements from contrast-enhanced data. Hepatol Res, 2018(epub ahead of print) (IF=3.415) Otsuka Y, Kamata K, Minaga K, Takenaka M, Watanabe T, Kudo M: Acute pancreatitis with disturbed consciousness caused by hyperparathyroidism. Internal Med 2018(epub ahead of print) (IF=0.817) Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K: Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer. J Thorac Oncol, 2018(epub ahead of print)

10 (IF=10.336) Tateishi R, Seike M, Kudo M, Tamai H, Kawazoe S, Katsube T, Ochiai T, Fukuhara T, Kano T, Tanaka K, Kurokawa M, Yamamoto K, Osaki Y, Izumi N, Imawari M: A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol, 2018 (epub ahead of print) (IF=5.561) Yoshida A, Yamao K, Takenaka M, Nakai A, Omoto S, Kamata K, Minaga K, Miyata T, Imai H, Matsumoto I, Takeyama Y, Chikugo T, Kudo M: Neurilemmoma Mimicking a Multilocular Cystic Lesion of the Liver: A Case Report. Intern Med, 2018 (epub ahead of print) (IF=0.817) Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, Kudo M, Nagasaka T: Heterogeneity of epigenetic and epithelial mesenchymal transition marks in hepatocellular carcinoma with keratin 19 proficiency. Liver Cancer, 2018 (epub ahead of print) (IF=7.854) Minaga K, Yamashita Y, Ogura T, Takenaka M, Shimokawa Y, Hisa T, Itonaga M, Kato H, Nishikiori H, Okuda A, Matsumoto H, Uenoyama Y, Watanabe T, Chiba Y, Higuchi K, Kudo M, Kitano M: Clinical efficacy and safety of EUS-guided gallbladder drainage replacement of percutaneous drainage: A multicenter retrospective study. Dig Endosc, 2018(epub ahead of print) (IF=3.238) Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX: Corrigendum to Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line

11 therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer, 2018(epub ahead of print) (IF=7.191) Kudo M: Ramucirumab as second-line systemic therapy in hepatocellular carcinoma. Liver Cancer, 2018(epub ahead of print) (IF=7.854) Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E: Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: A propensity score analysis. Liver Cancer, 2018(epub ahead of print) (IF=7.854) Takenaka M, Minaga K, Kudo M: ENBD tube-guided scope insertion technique for internal drainage in a case of difficult selective biliary duct guiding. Dig Endosc, 2018(epub ahead of print) (IF=3.238) Uchida S, Oiso N, Komeda Y, KudoM, Kawada A: Paradoxical ulcerative colitis during treatment with secukinumab for psoriasis. Eur J Dermatol, 2018 (epub ahead of print) (IF=1.944) Yamashita Y, Shimokawa T, Napoléon B, Fusaroli P, Gincul R, Kudo M, Kitano M: Value of contrast-enhanced harmonic EUS with enhancement pattern for diagnosis of pancreatic cancer: a meta-analysis. Dig Endosc, 2018 (epub ahead of print) (IF=3.238).

12 Yoshikawa T, Watanabe T, Minaga K, Kamata K, Kudo M: Cytokines produced by innate immune cells in IgG4-related disease. Mod Rheumatol, 2018 (epub ahead of print) (IF=1.955) Omoto S, Takenaka M, Kudo M: A case of EUS-guided pancreatic duct rendezvous stenting in which initial contrast medium injection was useful for the second puncture. Dig Endosc, 2018 (epub ahead of print) (IF=3.238) Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, Shi K, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Mazzaferro V, Garćia-Fiňana M, Kudo M, Kumada T, Roayaie S, Johnson PJ: Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J Hepatol, 2018 (epub ahead of print) (IF=14.911) Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG: Liver ultrasound elastography: An update to the World Federation for Ultrasound in Medicine and Biology guidelines and recommendations. Ultrasound Med Biol, 2018 (epub ahead of print) (IF=2.645) Lencioni R, Kudo M, Venook A, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Marrero JA: Second IA of the GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafenib) non-interventional study. Liver Int 2018 (in press) (IF=4.500) Nishikawa H, Enomoto H, Saito M, Aizawa N, Tsuda Y, Higuchi K, Okazaki K, Seki K, Seki T, Kim SR, Hongo Y, Jyomura H, Nishida N,

13 Kudo M, Osaki Y, Nishiguchi S: Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study. Acta Gastro-Ent Belg 2018 (in press) (IF=0.630) Takenaka M, Kamata K, Kudo M: Case of portal vein stenting for portal vein stenosis by bile duct cancer. Digest Liver Dis, 2018(in press) (IF=3.287) Kamata K, Watanabe T, Minaga K, Strober W, Kudo M: A mouse model of autoimmune paancreatitis. Curr Protoc Immunol, 2018 (in press) (IF=0.000) Takenaka M, Okabe Y, Yagi Y, Aakaki A, Kobayashi T, Shiomi H, Masuda A, Kudo M: Hemorrhage from 5mm Renal Cell Carcinoma Metastasis to the Gallbladder Detected by Contarast-Enhanced EUS. Am J Gastroenterol 2018 (in press) (IF=10.231) Zhu AX, Kang YK, Yen CJ, Finn RS, Galle P, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following first-line sorafenib (REACH-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2018 (in press) (IF=53.254) Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, Kudo M: Molecular scoring of hepatocellular carcinoma for predicting metastatic recurrence and requirements of systemic chemotherapy. Cancers, 2018 (in press) (IF=5.326).

14 Hiraoka A, Kumada T, Michitaka K, Kudo M: Newly proposed ALBI grade and ALBI-T score as tools for assessment of hepatic function and prognosis in hepatocellular carcinoma patients. Liver Cancer, 2018 (in press) (IF=7.854) Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kokudo T, Kashiwabara K, Kudo M and the Liver Cancer Study Group of Japan: Prediction of prognosis of intermediate stage HCC patients validation of tumor marker score in nationwide database in Japan. Liver Cancer, 2018 (in press) (IF=7.854) Takeda H, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y, Kudo M: Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion: a case report. Hepatol Res, 2018 (in press) (IF=3.415) Kudo M: Systemic therapy for hepatocellular carcinoma: Latest advances. Cancers, 2018 (in press) (IF=5.326).